StreetAlpha.app
Home › Stocks › STTK

Shattuck Labs, Inc. (STTK)

Healthcare
$4.46
▼ −1.98%
LAST CLOSE · NOV 20

Shattuck Labs develops antibody treatments for inflammatory and immune diseases, led by its DR3 blocking candidate SL-325. It last closed at $4.46 on Nov 20, down 1.98% on the day. The next earnings report for STTK is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, STTK reported EPS of -$0.14 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 5.7% the session after earnings. Over the last 12 months STTK insiders bought $250K of stock on the open market and sold $592K, according to SEC Form 4 filings.

AI Auto Pilots
Is STTK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold STTK.

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$67.7M
EPS (diluted)
−$0.47
Free cash flow
−$49.8M
Valuation
Market cap
$454.2M
101.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$61.8M
At Sep 30
Shareholder equity
$193.7M
Shares outstanding
101.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $30.0M$30.0MFY2021FY2022: $652K$652KFY2022FY2023: $1.7M$1.7MFY2023FY2024: $5.7M$5.7MFY2024FY2025: $1.0M$1.0MFY2025

From STTK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.14
Quarter ended Sep 2026
Year ago EPS
-$0.14
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.37Dec '24Mar 2025: -$0.27Mar '25Jun 2025: -$0.24Jun '25Sep 2025: -$0.14Sep '25Dec 2025: -$0.08Dec '25Mar 2026: -$0.13Mar '26Jun 2026: -$0.12Jun '26Sep 2026: -$0.14Sep '26Latest -$0.14
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $1.0MSep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How STTK moved after its last 8 reports
Average move the session after a report ±5.7%
Nov 5, 2026Time not announced−12.8%
Aug 11, 2026Time not announced+0.6%
May 7, 2026Time not announced−6.3%
Mar 5, 2026Time not announced+7.8%
Nov 6, 2025After the close+1.0%
Aug 14, 2025Time not announced+6.1%
May 1, 2025After the close−7.8%
Mar 27, 2025Time not announced−3.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on STTKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on STTK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on STTK

Technical Analysis

STTK · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 26% below its 50 day average. It is 36% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Nov 6) at $4.38, and the nearest resistance the Pivot at $4.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.3%/day
Key levels
$8.3352 week high+86.8%
$6.36100 day average+42.6%
$6.09200 day average+36.5%
$5.6150 day average+25.8%
$5.10Swing high (Jun 15)+14.3%
$5.0320 day average+12.8%
$4.62Pivot R1+3.6%
$4.52Pivot+1.3%
$4.46Last close
$4.38Swing low (Nov 6)−1.8%
$4.36Pivot S1−2.2%
$1.8852 week low−57.8%
Indicators
RSI (14)35.50Weak, oversold below 30Neutral
MACD-0.34Below its signal lineBearish
Stochastic11.2Near the bottom of its rangeOversold
ADX (14)22.6Weak trend
Williams %R-91.1Oversold below −80, overbought above −20Oversold
CCI (20)-84.8Oversold below −100, overbought above 100Neutral
Rate of change−3.5%Change over 10 sessionsBearish
ATR (14)$0.37Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for STTK

What happened before

See how STTK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow STTK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How STTK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for STTKHow many large options trades hit STTK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

STTK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲83 buying vs 34 selling
  • ▲Held by funds +7.1 pts
  • ▲Funds holding +16
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding116100+16.0%
In funds' top 10440.0%
Held by funds89.3%82.3%+7.1 pts
New / increased33 / 5037 / 35+15.3%
Reduced / sold out16 / 1815 / 20−2.9%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STTK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

STTK Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$250K1 buy · 1 insider
Sold$592K5 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-05 sold $213K2026-06 bought $250K2026-06 sold $210K2026-07 sold $169KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 2Abhinav A. ShuklaChief Technical OfficerSale plan410$7.01$3K
Jul 1Abhinav A. ShuklaChief Technical OfficerSale plan23,465$7.08$166K
Jun 30Arundathy N. PanditeChief Medical OfficerSale plan30,000$7.01$210K
Jun 9Clay B SiegallDirectorBuy62,500$4.00$250K
May 12Arundathy N. PanditeChief Medical OfficerSale plan30,000$6.61$198K
May 12Abhinav A. ShuklaChief Technical OfficerSale plan2,032$7.01$14K
Every insider buy and sale for STTK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See STTK insider trades →

From SEC Form 4 filings by STTK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STTK is in one of them and how their past STTK trades turned out.

STTK in the AI portfolios
Loading…

STTK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STTK in an article yet. Here's the latest on the wider market.

STTK in the news

About Shattuck Labs

Shattuck Labs is a biotechnology company based in Austin, Texas, that develops antibody treatments for inflammatory and immune diseases. Its lead candidate, SL-325, is designed to block the DR3 receptor, the only known receptor for the immune signaling molecule TL1A. The company is testing SL-325 in early clinical trials, with a planned focus on inflammatory bowel disease, and is also developing related antibodies. Its intended patients are people living with these conditions.

Headquarters
Austin, TX